Clinical activity of ipilimumab in acral melanoma: A retrospective review Journal Article
| Authors: | Johnson, D. B.; Peng, C.; Abramson, R. G.; Ye, F.; Zhao, S.; Wolchok, J. D.; Sosman, J. A.; Carvajal, R. D.; Ariyan, C. E. |
| Article Title: | Clinical activity of ipilimumab in acral melanoma: A retrospective review |
| Abstract: | Back ground. Ipilimumab improves overall survival (OS) in advanced melanoma. Acral melanoma is an uncommon clinical subtype of this disease associated with poor prognosis. The clinical activity of ipilimumab has not been well-defined in advanced acral melanoma. Methods. We retrospectively reviewed the demographics, treatment history, and clinical outcomes for all patients with acral melanoma treated with ipilimumab from two academic centers between February 2006 and June 2013. Using Cox proportional hazards models, we assessed for factors that correlated with OS. Results. A total of 35 patients with acral melanoma received ipilimumab. Melanomas arose on volar surfaces (n = 28) and subungual sites (n = 7); stage M1c disease was present in 54%, and 45% had elevated serum lactate dehydrogenase (LDH). Best response by RECIST 1.1 criteria was complete response in 1 patient, partial response in 3, and stable disease (SD) in 4 for an objective response rate (ORR) of 11.4% and a clinical benefit rate (ORR + SD) at 24 weeks of 22.9%. Median progression-free survival was 2.5 months (95% confidence interval [CI]: 2.3-2.7 months); median OS was 16.7 months (95% CI: 10.9-22.5 months). Normal LDH and absolute lymphocyte count $ 1,000 at 7 weeks predicted longer OS. Immune-related adverse events (irAEs) were noted in 16 patients including 7 with grade 3/4 irAEs (20%). Conclusion. Ipilimumab is clinically active in acral melanoma with similar ORR and OS compared with unselected melanoma populations. Ipilimumab remains a viable therapeutic option for patients with advanced acral melanoma. ©Alpha Med Press 2015 |
| Keywords: | adult; clinical article; aged; gene mutation; overall survival; cancer recurrence; drug efficacy; drug safety; skin toxicity; cancer staging; follow up; ipilimumab; melanoma; progression free survival; liver toxicity; retrospective study; drug response; colitis; lactate dehydrogenase; ctla-4; hydrocortisone; levothyroxine; lymphocyte count; ckit; hypophysitis; acral melanoma; immune therapy; very elderly; human; male; female; priority journal; article; acral |
| Journal Title: | The Oncologist |
| Volume: | 20 |
| Issue: | 6 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2015-06-01 |
| Start Page: | 648 |
| End Page: | 652 |
| Language: | English |
| DOI: | 10.1634/theoncologist.2014-0468 |
| PROVIDER: | scopus |
| PUBMED: | 25964307 |
| PMCID: | PMC4571784 |
| DOI/URL: | |
| Notes: | Export Date: 3 August 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work